Can-Fite BioPharma Ltd, a biotechnology company accelerating a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, has announced that its veterinary development and commercialization partner, Vetbiolix,has launched a safety and efficacy study of piclidenoson for the treatment of canine osteoarthritis.Safety findings are expected in the first quarter of 2022, and efficacy data are expected in the fourth quarter of 2022, according to a company release.1 Piclidenoson has been extensively tested in human clinical trials, with a favorable safety profile across over 1500 human patients.
展开▼
